Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

Impact · against what's priced in

Decoy Therapeutics has secured immediate liquidity to transition its lead asset into clinical trials, alongside a milestone-based funding structure. This reduces immediate insolvency risk and provides a path to Phase 2a data, representing a positive shift in the company's funding profile.

DCOY+0.50: No priced-in read yet
In context: The company secured $3.5 million in immediate gross proceeds to advance its lead asset into clinical trials, with an additional $17.5 million available upon meeting regulatory and clinical milestones.
Read from the article alone

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

private placement▲400%
biotech
healthcare
DCOY
antiviral
capital raise
clinical trials
financing
pipe

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

What matters in this story

ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

What matters in this story

ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?

How each ticker is affected

Track these names every morning.

2 healthcare stocks to turn $10 into $100 by next year

TransMedics: 2027 Setting Up To Be A Pivotal Year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

What matters in this story

Next reads from the same story arc

ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

What matters in this story

Next reads from the same story arc

ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?

How each ticker is affected

Track these names every morning.

2 healthcare stocks to turn $10 into $100 by next year

TransMedics: 2027 Setting Up To Be A Pivotal Year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline